251
Views
34
CrossRef citations to date
0
Altmetric
Reviews

Advances in pneumococcal antibiotic resistance

Pages 491-498 | Published online: 09 Jan 2014

References

  • Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr. Opin. Pulm. Med. 16(3), 217–225 (2010).
  • Blasi F, Mantero M, Santus P, Tarsia P. Understanding the burden of pneumococcal disease in adults. Clin. Microbiol. Infect. 18( Suppl. 5), 7–14 (2012).
  • Hansman D, Bullen MM. A resistant pneumococcus. Lancet 290(7509), 264–265 (1967).
  • Kislak JW. Type 6 pneumococcus resistant to erythromycin and lincomycin. N. Engl. J. Med. 276(15), 852 (1967).
  • Piddock LJ, Wise R. The selection and frequency of streptococci with decreased susceptibility to ofloxacin compared with other quinolones. J. Antimicrob. Chemother. 22( Suppl. C), 45–51 (1988).
  • Jacobs MR, Koornhof HJ, Robins-Browne RM et al. Emergence of multiply resistant pneumococci. N. Engl. J. Med. 299(14), 735–740 (1978).
  • Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365(9459), 579–587 (2005).
  • Chen DK, Mcgeer A, De Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N. Engl. J. Med. 341(4), 233–239 (1999).
  • Lynch JP 3rd, Zhanel GG. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy. Semin. Respir. Crit. Care Med. 26(6), 575–616 (2005).
  • Centers for Disease Control and Prevention. Progress in introduction of pneumococcal conjugate vaccine–worldwide, 2000–2008. Morb. Mortal. Wkly. Rep. 57(42), 1148–1151 (2008).
  • Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 28(26), 4249–4259 (2010).
  • Jones RN, Sader HS, Mendes RE, Flamm RK. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998–2011). Diagn. Microbiol. Infect. Dis. 75(1), 107–109 (2013).
  • Riedel S, Beekmann SE, Heilmann KP et al. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur. J. Clin. Microbiol. Infect. Dis. 26(7), 485–490 (2007).
  • Kim SH, Song JH, Chung DR et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob. Agents Chemother. 56(3), 1418–1426 (2012).
  • Song JH, Chang HH, Suh JY et al. Macrolide resistance and genotypic characterization of Streptococcus pneumoniae in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens (ANSORP). J. Antimicrob. Chemother. 53(3), 457–463 (2004).
  • Song JH, Jung SI, Ko KS et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob. Agents Chemother. 48(6), 2101–2107 (2004).
  • Harimaya A, Yokota S, Sato K, Yamazaki N, Himi T, Fujii N. High prevalence of erythromycin resistance and macrolide-resistance genes, mefA and ermB, in Streptococcus pneumoniae isolates from the upper respiratory tracts of children in the Sapporo district, Japan. J. Infect. Chemother. 13(4), 219–223 (2007).
  • Song JH, Lee NY, Ichiyama S et al. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Clin. Infect. Dis. 28(6), 1206–1211 (1999).
  • Edelstein PH. Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: molecular mechanisms and resistance phenotypes. Clin. Infect. Dis. 38( Suppl. 4), S322–S327 (2004).
  • Wierzbowski AK, Swedlo D, Boyd D et al. Molecular epidemiology and prevalence of macrolide efflux genes mef(A) and mef(E) in Streptococcus pneumoniae obtained in Canada from 1997 to 2002. Antimicrob. Agents Chemother. 49(3), 1257–1261 (2005).
  • Felmingham D, Canton R, Jenkins SG. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001–2004. J. Infect. 55(2), 111–118 (2007).
  • Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg. Infect. Dis. 15(8), 1260–1264 (2009).
  • Farrell DJ, Jenkins SG, Brown SD, Patel M, Lavin BS, Klugman KP. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg. Infect. Dis. 11(6), 851–858 (2005).
  • Wierzbowski AK, Nichol K, Laing N et al. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004). J. Antimicrob. Chemother. 60(4), 733–740 (2007).
  • Moore MR, Gertz RE Jr., Woodbury RL et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis. 197(7), 1016–1027 (2008).
  • Bowers JR, Driebe EM, Nibecker JL et al. Dominance of multidrug resistant CC271 clones in macrolide-resistant Streptococcus pneumoniae in Arizona. BMC Microbiol. 12, 12 (2012).
  • Ko KS, Song JH. Evolution of erythromycin-resistant Streptococcus pneumoniae from Asian countries that contains erm(B) and mef(A) genes. J. Infect. Dis. 190(4), 739–747 (2004).
  • Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. The impact of the pneumococcal conjugate vaccine on antimicrobial resistance in the United States since 1996: evidence for a significant rebound by 2007 in many classes of antibiotics. Microb. Drug Resist. 15(4), 261–268 (2009).
  • Green K, Mcgeer A, Wong K et al. What will happen to antimicrobial resistance in adult IPD after the introduction of infant PCV13 vaccination in Canada? Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 9–12 September 2012.
  • Kaplan SL, Barson WJ, Lin PL et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 32(3), 203–207 (2013).
  • Kyaw MH, Lynfield R, Schaffner W et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354(14), 1455–1463 (2006).
  • Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. Impact of new Clinical Laboratory Standards Institute Streptococcus pneumoniae penicillin susceptibility testing breakpoints on reported resistance changes over time. Microb. Drug Resist. 17(1), 47–52 (2011).
  • Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin. Infect. Dis. 48(11), 1596–1600 (2009).
  • Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. CLSI Document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA, USA (2010).
  • Centers for Disease Control and Prevention. Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae – United States, 2006–2007. MMWR Morb. Mortal. Wkly. Rep. 57(50), 1353–1355 (2008).
  • Su LH, Wu TL, Kuo AJ, Chia JH, Chiu CH. Antimicrobial susceptibility of Streptococcus pneumoniae at a university hospital in Taiwan, 2000–07: impact of modified non-meningeal penicillin breakpoints in CLSI M100-S18. J. Antimicrob. Chemother. 64(2), 336–342 (2009).
  • Linares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin. Microbiol. Infect. 16(5), 402–410 (2010).
  • Cornick JE, Bentley SD. Streptococcus pneumoniae: the evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides. Microbes Infect. 14(7–8), 573–583 (2012).
  • Nichol KA, Zhanel GG, Hoban DJ. Penicillin-binding protein 1A, 2B, and 2X alterations in Canadian isolates of penicillin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46(10), 3261–3264 (2002).
  • Zapun A, Contreras-Martel C, Vernet T. Penicillin-binding proteins and beta-lactam resistance. FEMS Microbiol. Rev. 32(2), 361–385 (2008).
  • Chi F, Nolte O, Bergmann C, Ip M, Hakenbeck R. Crossing the barrier: evolution and spread of a major class of mosaic pbp2x in Streptococcus pneumoniae, S. mitis and S. oralis. Int. J. Med. Microbiol. 297(7–8), 503–512 (2007).
  • Reinert RR, Reinert S, Van Der Linden M, Cil MY, Al-Lahham A, Appelbaum P. Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob. Agents Chemother. 49(7), 2903–2913 (2005).
  • Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1–4. Ann. Clin. Microbiol. Antimicrob. 7, 1 (2008).
  • Coffey TJ, Dowson CG, Daniels M, Spratt BG. Genetics and molecular biology of beta-lactam-resistant pneumococci. Microb. Drug Resist. 1(1), 29–34 (1995).
  • Nagai K, Davies TA, Jacobs MR, Appelbaum PC. Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob. Agents Chemother. 46(5), 1273–1280 (2002).
  • Maurer P, Todorova K, Sauerbier J, Hakenbeck R. Mutations in Streptococcus pneumoniae penicillin-binding protein 2x: importance of the C-terminal penicillin-binding protein and serine/threonine kinase-associated domains for beta-lactam binding. Microb. Drug Resist. 18(3), 314–321 (2012).
  • Low DE. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin. Infect. Dis. 38( Suppl. 4), S357–S362 (2004).
  • Adam HJ, Hoban DJ, Gin AS, Zhanel GG. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997–2006. Int. J. Antimicrob. Agents 34(1), 82–85 (2009).
  • Bhavnani SM, Hammel JP, Jones RN, Ambrose PG. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn. Microbiol. Infect. Dis. 51(1), 31–37 (2005).
  • Norskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004–2007). Int. J. Antimicrob. Agents 34(2), 121–130 (2009).
  • Li X, Zhao X, Drlica K. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob. Agents Chemother. 46(2), 522–524 (2002).
  • Janoir C, Zeller V, Kitzis MD, Moreau NJ, Gutmann L. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40(12), 2760–2764 (1996).
  • Balsalobre L, De La Campa AG. Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes. Antimicrob. Agents Chemother. 52(3), 822–830 (2008).
  • Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin. Infect. Dis. 34(4), 482–492 (2002).
  • Jorgensen JH, Mcelmeel ML, Fulcher LC, Mcgee L, Glennen A. Evaluation of disk approximation and single-well broth tests for detection of inducible clindamycin resistance in Streptococcus pneumoniae. J. Clin. Microbiol. 49(9), 3332–3333 (2011).
  • Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections – full version. Clin. Microbiol. Infect. 17( Suppl. 6), E1–E59 (2011).
  • Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44( Suppl. 2), S27–S72 (2007).
  • Dallas SD, Mcgee L, Limbago B et al. Development of doxycycline MIC and disk diffusion interpretive breakpoints and revision of tetracycline breakpoints for Streptococcus pneumoniae. J. Clin. Microbiol. 51(6), 1798–1802 (2013).
  • Van Bambeke F, Reinert RR, Appelbaum PC, Tulkens PM, Peetermans WE. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs 67(16), 2355–2382 (2007).
  • Draghi DC, Jones ME, Sahm DF, Tillotson GS. Geographically-based evaluation of multidrug resistance trends among Streptococcus pneumoniae in the USA: findings of the FAST surveillance initiative (2003–2004). Int. J. Antimicrob. Agents 28(6), 525–531 (2006).
  • Farrell DJ, Couturier C, Hryniewicz W. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003–2004). Int. J. Antimicrob. Agents 31(3), 245–249 (2008).
  • Lynch JP, 3rd, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin. Respir. Crit. Care Med. 30(2), 210–238 (2009).
  • Gertz RE Jr., Li Z, Pimenta FC et al. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J. Infect. Dis. 201(5), 770–775 (2010).
  • Shin J, Baek JY, Kim SH, Song JH, Ko KS. Predominance of ST320 among Streptococcus pneumoniae serotype 19A isolates from 10 Asian countries. J. Antimicrob. Chemother. 66(5), 1001–1004 (2011).
  • Beall BW, Gertz RE, Hulkower RL, Whitney CG, Moore MR, Brueggemann AB. Shifting genetic structure of invasive serotype 19A pneumococci in the United States. J. Infect. Dis. 203(10), 1360–1368 (2011).
  • Hulten KG, Kaplan SL, Lamberth LB et al. Changes in Streptococcus pneumoniae serotype 19A invasive infections in children from 1993 to 2011. J. Clin. Microbiol. 51(4), 1294–1297 (2013).
  • Vestrheim DF, Steinbakk M, Aaberge IS, Caugant DA. Postvaccination increase in serotype 19A pneumococcal disease in Norway is driven by expansion of penicillin-susceptible strains of the ST199 complex. Clin. Vaccine Immunol. 19(3), 443–445 (2012).
  • Green K, Mcgeer A, Wong K et al. Surveillance for antimicrobial resistance in Streptococcus pneumoniae in Canada, 1993–2011. Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 9–12 September 2012.
  • Kang CI, Baek JY, Jeon K et al. Bacteremic pneumonia caused by extensively drug-resistant Streptococcus pneumoniae. J. Clin. Microbiol. 50(12), 4175–4177 (2012).
  • Ko KS, Baek JY, Song JH. Multidrug-resistant Streptococcus pneumoniae serotype 6D clones in South Korea. J. Clin. Microbiol. 50(3), 818–822 (2012).
  • Niederman MS, Luna CM. Community-acquired pneumonia guidelines: a global perspective. Semin. Respir. Crit. Care Med. 33(3), 298–310 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.